Plain-English translation of NCT04546126 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging tracer called [18F]FNP-59 that helps doctors see how cholesterol travels through your body using a special camera (PET scanner). The medication is designed to provide clearer, safer images than older versions, with less radiation exposure to your thyroid. Researchers want to understand how the tracer works in healthy people and in people with adrenal gland conditions.
Current imaging methods for tracking cholesterol in the body have limitations—they use older tracers that expose your thyroid to radiation and don't always show a clear picture. This study aims to prove that this new treatment provides better image quality and safety, which could help doctors diagnose adrenal and cholesterol-related problems more accurately in the future.
You likely qualify if…
You likely don't qualify if…
If you're in Groups 2 or 3, you'll have two PET scans about four days apart; between scans, you'll take a medication to either suppress or stimulate your hormones for a few days. If you're in Group 4 (with adrenal problems), you'll have two PET scans on the same day, at different time points, with no hormone manipulation. All scans involve receiving an injection of the tracer and lying still while the camera takes images—typically taking 1–2 hours per visit.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States